ETINZUE Trademark

Trademark Overview


On Monday, May 24, 2021, a trademark application was filed for ETINZUE with the United States Patent and Trademark Office. The USPTO has given the ETINZUE trademark a serial number of 90729627. The federal status of this trademark filing is FOURTH EXTENSION - GRANTED as of Tuesday, October 15, 2024. This trademark is owned by Bristol-Myers Squibb Company. The ETINZUE trademark is filed in the Pharmaceutical Products category with the following description:

Pharmaceutical preparations for human use for the treatment and prevention of obesity, incontinence, cardiovascular diseases, central nervous system diseases and disorders, metabolic disorders, stroke, cancer, inflammation and inflammatory diseases, respiratory and infectious diseases, auto-immune diseases, solid organ transplant rejection, beta thalassemia and myelodysplastic syndromes, myeloproliferative diseases, myelofibrosis, leukemia, lymphoma, multiple myeloma, autoinflammatory disease, blood disease, tumors, multiple sclerosis, ulcerative colitis, arthritis, and musculoskeletal and skin diseases; Pharmaceutical preparations for human use, namely, antibiotics, anti-fungals, anti-virals, immunosuppressants, pharmaceutical antibodies, immunotherapies for the treatment of cancer, cytokine inhibitory drugs; Pharmaceutical preparations for human use that modulate the immune system; Pharmaceutical and biological preparations for human use for immunotherapy, namely T Cell therapy; Phar...
etinzue

General Information


Serial Number90729627
Word MarkETINZUE
Filing DateMonday, May 24, 2021
Status733 - FOURTH EXTENSION - GRANTED
Status DateTuesday, October 15, 2024
Registration Number0000000
Registration DateNOT AVAILABLE
Mark Drawing4 - Illustration: Drawing with word(s) / letter(s) / number(s) in Block form
Published for Opposition DateTuesday, August 23, 2022

Trademark Statements


Goods and ServicesPharmaceutical preparations for human use for the treatment and prevention of obesity, incontinence, cardiovascular diseases, central nervous system diseases and disorders, metabolic disorders, stroke, cancer, inflammation and inflammatory diseases, respiratory and infectious diseases, auto-immune diseases, solid organ transplant rejection, beta thalassemia and myelodysplastic syndromes, myeloproliferative diseases, myelofibrosis, leukemia, lymphoma, multiple myeloma, autoinflammatory disease, blood disease, tumors, multiple sclerosis, ulcerative colitis, arthritis, and musculoskeletal and skin diseases; Pharmaceutical preparations for human use, namely, antibiotics, anti-fungals, anti-virals, immunosuppressants, pharmaceutical antibodies, immunotherapies for the treatment of cancer, cytokine inhibitory drugs; Pharmaceutical preparations for human use that modulate the immune system; Pharmaceutical and biological preparations for human use for immunotherapy, namely T Cell therapy; Pharmaceutical preparations for human use, namely, stem cells for medical or clinical use; Pharmaceutical preparations for treatment or prevention of covid-19, coronavirus disease, and respiratory diseases and disorders; antivirals for treatment or prevention of covid-19, coronavirus disease, and respiratory diseases and disorders; monoclonal antibodies

Classification Information


International Class005 - Pharmaceutical and veterinary preparations; sanitary preparations for medical purposes; dietetic substances adapted for medical use, food for babies; plasters, materials for dressings; material for stopping teeth, dental wax; disinfectants; preparations for destroying vermin; fungicides, herbicides.
US Class Codes005, 006, 018, 044, 046, 051, 052
Class Status Code6 - Active
Class Status DateThursday, August 19, 2021
Primary Code005
First Use Anywhere DateNOT AVAILABLE
First Use In Commerce DateNOT AVAILABLE

Trademark Owner History


Party NameBristol-Myers Squibb Company
Party Type20 - Owner at Publication
Legal Entity Type03 - Corporation
AddressPrinceton, NJ 08543

Party NameBristol-Myers Squibb Company
Party Type10 - Original Applicant
Legal Entity Type03 - Corporation
AddressNew York, NY 10016

Trademark Events


Event DateEvent Description
Tuesday, December 28, 2021NON-FINAL ACTION E-MAILED
Thursday, May 27, 2021NEW APPLICATION ENTERED
Thursday, August 19, 2021NEW APPLICATION OFFICE SUPPLIED DATA ENTERED
Monday, December 27, 2021ASSIGNED TO EXAMINER
Tuesday, December 28, 2021NON-FINAL ACTION WRITTEN
Tuesday, December 28, 2021NOTIFICATION OF NON-FINAL ACTION E-MAILED
Thursday, June 23, 2022TEAS RESPONSE TO OFFICE ACTION RECEIVED
Thursday, June 23, 2022CORRESPONDENCE RECEIVED IN LAW OFFICE
Thursday, June 23, 2022TEAS/EMAIL CORRESPONDENCE ENTERED
Thursday, July 21, 2022APPROVED FOR PUB - PRINCIPAL REGISTER
Wednesday, August 3, 2022NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED
Tuesday, August 23, 2022PUBLISHED FOR OPPOSITION
Tuesday, August 23, 2022OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED
Tuesday, October 18, 2022NOA E-MAILED - SOU REQUIRED FROM APPLICANT
Wednesday, March 29, 2023SOU TEAS EXTENSION RECEIVED
Wednesday, March 29, 2023SOU EXTENSION 1 FILED
Wednesday, March 29, 2023SOU EXTENSION 1 GRANTED
Friday, March 31, 2023NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
Wednesday, August 2, 2023TEAS CHANGE OF OWNER ADDRESS RECEIVED
Wednesday, August 2, 2023APPLICANT/CORRESPONDENCE CHANGES (NON-RESPONSIVE) ENTERED
Wednesday, August 2, 2023TEAS CHANGE OF CORRESPONDENCE RECEIVED
Thursday, October 5, 2023NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
Tuesday, October 3, 2023SOU TEAS EXTENSION RECEIVED
Tuesday, October 3, 2023SOU EXTENSION 2 FILED
Tuesday, October 3, 2023SOU EXTENSION 2 GRANTED
Thursday, March 14, 2024SOU TEAS EXTENSION RECEIVED
Thursday, March 14, 2024SOU EXTENSION 3 FILED
Thursday, March 14, 2024SOU EXTENSION 3 GRANTED
Friday, March 15, 2024NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
Tuesday, October 15, 2024SOU TEAS EXTENSION RECEIVED
Tuesday, October 15, 2024SOU EXTENSION 4 GRANTED
Tuesday, October 15, 2024SOU EXTENSION 4 FILED
Tuesday, October 15, 2024NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED